DIACOMIT 250mg capsules medication leaflet

Diacomit 100 mg hard capsules

Each capsule contains 100 mg of stiripentol.

For the full list of excipients, see section 6.1.

Hard capsule

Size 4, pink and white capsule, imprinted with “Diacomit 100 mg”, length of 14 mm.

Diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive therapy ofrefractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy(SMEI, Dravet’s syndrome) whose seizures are not adequately controlled with clobazam andvalproate.

Diacomit should only be administered under the supervision of a paediatrician/paediatric neurologistexperienced in the diagnosis and management of epilepsy in infants and children.

The dose of stiripentol is calculated on a mg/kg body weight basis.

The daily dosage may be administered in 2 or 3 divided doses.

The initiation of adjunctive therapy with stiripentol should be undertaken gradually using upwardsdose escalation to reach the recommended dose of 50 mg/kg/day administered in conjunction withclobazam and valproate.

Stiripentol dosage escalation should be gradual, starting with 20mg/kg/day for 1 week, then30mg/kg/day for 1 week. Further dosage escalation is age dependent:

- children less than 6 years should receive an additional 20 mg/kg/day in the third week, thusachieving the recommended dose of 50 mg/kg/day in three weeks;

- children from 6 to less than 12 years should receive an additional 10 mg/kg/day each week, thusachieving the recommended dose of 50 mg/kg/day in four weeks;

- children and adolescents 12 years and older should receive an additional 5 mg/kg/day each weekuntil the optimum dose is reached based on clinical judgment.

The recommended dose of 50 mg/kg/day is based on the available clinical study findings and was theonly dose of Diacomit evaluated in the pivotal studies (see section 5.1).

Stiripentol must always be taken with food as it degrades rapidly in an acidic environment (e.g.exposure to gastric acid in an empty stomach).

Stiripentol should not be taken with milk or dairy products (yoghurt, soft cream cheese, etc.),carbonated drinks, fruit juice or food and drinks that contain caffeine or theophylline.

Children aged less than 3 years

The pivotal clinical evaluation of stiripentol was in children of 3 years of age and over with SMEI.

The clinical decision for use of stiripentol in children with SMEI less than 3 years of age needs to bemade on an individual patient basis taking into consideration the potential clinical benefits and risks.

In this younger group of patients, adjunctive therapy with stiripentol should only be started when thediagnosis of SMEI has been clinically confirmed (see section 5.1). Data are limited about the use ofstiripentol under 12 months of age. For these children the use of stiripentol will be done under theclose supervision of the doctor.

Patients aged ≥ 18 years of age

Long-term data has not been collected in a sufficient number of adults to confirm maintenance ofeffect in this population. Treatment should be continued for as long as efficacy is observed.

Dose adjustments of other antiepileptics used in combination with stiripentol

Despite the absence of comprehensive pharmacology data on potential drug interactions, the followingadvice regarding modification of the dose and dosage schedules of other anti-epileptic medicinalproducts administered in conjunction with stiripentol is provided based on clinical experience.

- Clobazam

In the pivotal studies, when the use of stiripentol was initiated, the daily dose of clobazam was0.5 mg/kg/day usually administered in divided doses, twice daily. In the event of clinical signs ofadverse reactions or overdose of clobazam (i.e., drowsiness, hypotonia, and irritability in youngchildren), this daily dose was reduced by 25% every week. Approximately two to three-fold increasesin clobazam and five-fold increases in norclobazam plasma levels respectively have been reportedwith co-administration of stiripentol in children with Dravet’s syndrome.

- Valproate

The potential for metabolic interaction between stiripentol and valproate is considered modest andthus, no modification of valproate dosage should be needed when stiripentol is added, except forclinical safety reasons. In the pivotal studies in the event of gastrointestinal adverse reactions such asloss of appetite, loss of weight, the daily dose of valproate was reduced by around 30% every week.

Abnormal laboratory findings

In the event of an abnormal blood count or liver function test finding, the clinical decision forcontinuing use or adjusting the dose of stiripentol in conjunction with adjusting the doses of clobazamand valproate needs to be made on an individual patient basis taking into consideration the potentialclinical benefits and risks (see section 4.4).

Effect of formulation

The sachet formulation has a slightly higher Cmax than the capsules and thus the formulations are notbioequivalent. It is recommended that if a switch of formulations is required this is done under clinicalsupervision, in case of problems with tolerability (see section 5.2).

Stiripentol is not recommended for use in patients with impaired hepatic and/or renal function (seesection 4.4).

Oral use

The capsule should be swallowed whole with a glass of water.

To ensure that the whole amount of powder is taken by the patient, the capsule should not be opened.

For the interaction of stiripentol with food, please see section 4.5.

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

A past history of psychoses in the form of episodes of delirium.

Carbamazepine, phenytoin and phenobarbital

These substances should not be used in conjunction with stiripentol in the management of Dravet’ssyndrome. The daily dosage of clobazam and/or valproate should be reduced according to the onset ofside effects whilst on stiripentol therapy (see section 4.2).

Growth rate of children

Given the frequency of gastrointestinal adverse reactions to treatment with stiripentol and valproate(anorexia, loss of appetite, nausea, vomiting), the growth rate of children under this combination oftreatment should be carefully monitored.

Blood count

Neutropenia may be associated with the administration of stiripentol, clobazam and valproate. Bloodcounts should be assessed prior to starting treatment with stiripentol. Unless otherwise clinicallyindicated, blood counts should be checked every 6 months.

It should be assessed prior to starting treatment with stiripentol. Unless otherwise clinically indicated,liver function should be checked every 6 months.

Hepatic or renal impairment

In the absence of specific clinical data in patients with impaired hepatic or renal function, stiripentol isnot recommended for use in patients with impaired hepatic and/or renal function (see section 4.2).

Substances interfering with CYP enzymes

Stiripentol is an inhibitor of the enzymes CYP2C19, CYP3A4 and CYP2D6 and may markedlyincrease the plasma concentrations of substances metabolised by these enzymes and increase the riskof adverse reactions (see section 4.5). In vitro studies suggested that stiripentol phase 1 metabolism iscatalyzed by CYP1A2, CYP2C19 and CYP3A4 and possibly other enzymes. Caution is advised whencombining stiripentol with other substances that inhibit or induce one or more of these enzymes.

The pivotal clinical studies did not include children below 3 years old. As a consequence, it isrecommended that children between 6 months and 3 years of age are carefully monitored whilst onstiripentol therapy.

This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially‘sodium-free’.

Potential medicinal product interactions affecting stiripentol

The influence of other antiepileptic medicinal products on stiripentol pharmacokinetics is not wellestablished.

The impact of macrolides and azole antifungal medicinal products on stiripentol metabolism, that areknown to be inhibitors of CYP3A4 and substrates of the same enzyme, is not known. Likewise, theeffect of stiripentol on their metabolism is not known.

In vitro studies suggested that stiripentol phase 1 metabolism is catalyzed by CYP1A2, CYP2C19 and

CYP3A4 and possibly other enzymes. Caution is advised when combining stiripentol with othersubstances that inhibit or induce one or more of these enzymes.

Effect of stiripentol on cytochrome P450 enzymes

Many of these interactions have been partially confirmed by in vitro studies and in clinical trials. Theincrease in steady state levels with the combined use of stiripentol, valproate, and clobazam is similarin adults and children, though inter-individual variability is marked.

At therapeutic concentrations, stiripentol significantly inhibits several CYP450 isoenzymes: forexample, CYP2C19, CYP2D6 and CYP3A4. As a result, pharmacokinetic interactions of metabolicorigin with other medicines may be expected. These interactions may result in increased systemiclevels of these active substances that may lead to enhanced pharmacological effects and to an increasein adverse reactions.

Caution must be exercised if clinical circumstances require combining stiripentol with substancesmetabolised by CYP2C19 (e.g. citalopram, omeprazole) or CYP3A4 (e.g. HIV protease inhibitors,antihistamines such as astemizole and chlorpheniramine, calcium channel blockers, statins, oralcontraceptives, codeine) due to the increased risk of adverse reactions (see further in this section forantiepileptic medicines). Monitoring of plasma concentrations or adverse reactions is recommended. Adose adjustment may be necessary.

Co-administration with CYP3A4 substrates with a narrow therapeutic index should be avoided due tothe markedly increased risk of severe adverse reactions.

Data on the potential for inhibition of CYP1A2 are limited, and therefore, interactions withtheophylline and caffeine cannot be excluded because of the increased plasma levels of theophyllineand caffeine which may occur via inhibition of their hepatic metabolism, potentially leading totoxicity. Use in combination with stiripentol is not recommended. This warning is not only restrictedto medicinal products but also to a considerable number of foods (for example: cola, chocolate, coffee,tea, and energy drinks) and nutritional products aimed at children: Patient should not drink cola drinks,which contain significant quantities of caffeine or chocolate, which contains trace amounts oftheophylline (see section 4.2).

As stiripentol inhibited CYP2D6 in vitro at concentrations that are achieved clinically in plasma,substances that are metabolized by this isoenzyme like: beta-blockers (propranolol, carvedilol,timolol), antidepressants (fluoxetine, paroxetine, sertraline, imipramine, clomipramine), antipsychotics(haloperidol), analgesics (codeine, dextromethorphan, tramadol) may be subject to metabolicinteractions with stiripentol. A dose-adjustment may be necessary for substances metabolised by

CYP2D6 and that are individually dose titrated.

Potential for stiripentol to interact with other medicinal products

In the absence of available clinical data, caution should be taken with the following clinically relevantinteractions with stiripentol:

Undesirable combinations (to be avoided unless strictly necessary)

- Rye ergot alkaloids (ergotamine, dihydroergotamine)

Ergotism with possibility of necrosis of the extremities (inhibition of hepatic elimination of rye ergot).

- Cisapride, halofantrine, pimozide, quinidine, bepridil

Increased risk of cardiac arrhythmias and torsades de pointes/wave burst arrhythmia in particular.

- Immunosuppressants (tacrolimus, cyclosporine, sirolimus)

Raised blood levels of immunosuppressants (decreased hepatic metabolism).

- Statins (atorvastatin, simvastatin, etc.)

Increased risk of dose-dependent adverse reactions such as rhabdomyolysis (decreased hepaticmetabolism of cholesterol-lowering medicinal product).

Combinations requiring precautions

- Midazolam, triazolam, alprazolam

Increased plasma benzodiazepine levels may occur via decreased hepatic metabolism leading toexcessive sedation.

- Chlorpromazine

Stiripentol enhances the central depressant effect of chlorpromazine.

- Effects on other antiepileptic drugs (AEDs)

Inhibition of CYP450 isoenzyme CYP2C19 and CYP3A4 may provoke pharmacokinetic interactions(inhibition of their hepatic metabolism) with phenobarbital, primidone, phenytoin, carbamazepine,clobazam (see section 4.2), valproate (see section 4.2), diazepam (enhanced myorelaxation),ethosuximide, and tiagabine. The consequences are increased plasma levels of these anticonvulsantswith potential risk of overdose. Clinical monitoring of plasma levels of other anticonvulsants whencombined with stiripentol with possible dose adjustments is recommended.

- Topiramate

In a French compassionate use program for stiripentol, topiramate was added to stiripentol, clobazamand valproate in 41% of 230 cases. Based on the clinical observations in this group of patients, there isno evidence to suggest that a change in topiramate dose and dosage schedules is needed if co-administered with stiripentol.

With regard to topiramate, it is considered that potential competition of inhibition on CYP2C19 shouldnot occur because it probably requires plasma concentrations 5-15 times higher than plasmaconcentrations obtained with the standard recommended topiramate dose and dosage schedules.

- Levetiracetam

Levetiracetam does not undergo hepatic metabolism to a major extent. As a result, no pharmacokineticmetabolic drug interaction between stiripentol and levetiracetam is anticipated.

Risk related to epilepsy and antiepileptic medicinal products in general

It has been shown that in the offspring of women with epilepsy, the prevalence of malformations istwo to three times greater than the rate of approximately 3% in the general population. Although otherfactors, e.g. the epilepsy, can contribute, available evidence suggests that this increase, to a largeextent, is caused by the treatment. In the treated population, an increase in malformations has beennoted with polytherapy.

However, effective anti-epileptic therapy should not be interrupted during pregnancy, since theaggravation of the illness may be detrimental to both the mother and the foetus.

Risk related to stiripentol

No data on exposed pregnancies are available. Animal studies do not indicate direct or indirectharmful effects with respect to pregnancy, foetal development, parturition or postnatal development atnon-maternotoxic doses (see section 5.3). In view of the indication, administration of stiripentol duringpregnancy and in women of childbearing potential would not be expected. The clinical decision foruse of stiripentol in pregnancy needs to be made on an individual patient basis taking intoconsideration the potential clinical benefits and risks. Caution should be exercised when prescribing topregnant women and use of efficient methods of contraception is advisable.

In the absence of human studies on excretion in breast milk, and given that stiripentol passes freelyfrom plasma into milk in the goat, breast-feeding is not recommended during treatment. In casestiripentol therapy is continued during breast-feeding, the breast-fed infant should be carefullyobserved for potential adverse effects.

No impact on fertility was detected in animal studies (see section 5.3). No clinical data are available,potential risk for human is unknown.

Stiripentol has major influence on the ability to drive and use machines because it may cause dizzinessand ataxia. Patients should be advised not to drive or use machines until they have gained sufficientexperience to gauge whether it adversely affects their abilities (see section 4.8).

The most common side effects with stiripentol are anorexia, weight loss, insomnia, drowsiness, ataxia,hypotonia and dystonia.

Adverse reactions encountered most often are as follows: very common (≥ 1/10), common (≥ 1/100 to< 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), notknown (cannot be estimated from the available data). Within each frequency grouping, undesirableeffects are presented in order of decreasing severity.

System Organ Very common Common Uncommon Rare

Class(MedDRAterminology)

Blood and Neutropenia Thrombocytopenialymphatic *systemdisorders

Metabolism and Anorexia, loss ofnutrition appetite, weightdisorders loss

Psychiatric Insomnia Aggressiveness,disorders irritability, behaviourdisorders, opposingbehaviour,hyperexcitability,sleep disorders

Nervous system Drowsiness, Hyperkinesiasdisorders ataxia,hypotonia,dystonia

Eye disorders Diplopia

Gastrointestinal Nausea, vomitingdisorders

Skin and Photosensitivity,subcutaneous rash, cutaneoustissue disorders allergy, urticaria

General Fatiguedisorders andadministrationsite conditions

Investigations Raised γ-GT Liver function testabnormal

* Thrombocytopenia data are derived from both clinical trials and post-marketing experience.

Many of the above adverse reactions are often due to an increase in plasma levels of otheranticonvulsant medicinal products (see sections 4.4 and 4.5) and may regress when the dose of thesemedicinal products is reduced.

Reporting suspected adverse reactions after authorisation of the medicinal product is important. Itallows continued monitoring of the benefit/risk balance of the medicinal product. Healthcareprofessionals are asked to report any suspected adverse reactions via the national reporting systemlisted in Appendix V.

Data on clinical overdose are not available. Treatment is supportive (symptomatic measures inintensive care units).

Pharmacotherapeutic group: Antiepileptics, other antiepileptics, ATC code: N03AX17

In animal models, stiripentol antagonizes seizures induced by electric shock, pentetrazole andbicuculline. In rodent models, stiripentol appears to increase brain levels of gamma-aminobutyric acid(GABA) - the major inhibitory neurotransmitter in mammalian brain. This could occur by inhibition ofsynaptosomal uptake of GABA and/or inhibition of GABA transaminase. Stiripentol has also beenshown to enhance GABAA receptor-mediated transmission in the immature rat hippocampus andincrease the mean open-duration (but not the frequency) of GABAA receptor chloride channels by abarbiturate-like mechanism. Stiripentol potentiates the efficacy of other anticonvulsants, such ascarbamazepine, sodium valproate, phenytoin, phenobarbital and many benzodiazepines, as the resultof pharmacokinetic interactions. The second effect of stiripentol is mainly based on metabolicinhibition of several isoenzymes, in particular CYP450 3A4 and 2C19, involved in the hepaticmetabolism of other anti-epileptic medicines.

The pivotal clinical evaluation of stiripentol was in children of 3 years of age and over with SMEI.

A French compassionate use program included children from 6 months of age because the diagnosis of

Dravet’s syndrome may be made with confidence at that age in some patients. The clinical decision foruse of Diacomit in children with SMEI less than 3 years of age needs to be made on an individualpatient basis taking into consideration the potential clinical benefits and risks (see section 4.2).

41 children with SMEI were included in a randomised, placebo-controlled, add-on trial. After abaseline period of 1 month, placebo (n=20) or stiripentol (n=21) was added to valproate and clobazamduring a double-blind period of 2 months. Patients then received stiripentol in an open fashion.

Responders were defined as having more than 50% reduction in the frequency of clonic (or tonic-clonic) seizures during the second month of the double-blind period compared with baseline. 15 (71%)patients were responders on stiripentol (including nine free of clonic or tonic-clonic seizures), whereasthere was only one (5%) on placebo (none was seizure free; stiripentol 95% CI 52.1-90.7 vs. placebo0-14.6). The 95% CI of the difference was 42.2-85.7. Percentage of change from baseline was higheron stiripentol (-69%) than on placebo (+7%), p< 0.0001. 21 patients on stiripentol had moderate side-effects (drowsiness, loss of appetite) compared with eight on placebo, but side-effects disappearedwhen the dose of comedication was decreased in 12 of the 21 cases (Chiron et al, Lancet, 2000).

There are no clinical study data to support the clinical safety of stiripentol administered at daily dosesgreater than 50 mg/kg/day. There are no clinical study data to support the use of stiripentol asmonotherapy in Dravet’s syndrome.

The following pharmacokinetic properties of stiripentol have been reported from studies in adulthealthy volunteers and adult patients.

Stiripentol is quickly absorbed, with a time to peak plasma concentration of about 1.5 hours. Theabsolute bioavailability of stiripentol is not known since an intravenous formulation is not availablefor testing. It is well absorbed by the oral route since the majority of an oral dose is excreted in urine.

Relative bioavailability between the capsules and powder for oral suspension in sachet formulationshas been studied in healthy male volunteers after a 1,000 mg single oral administration. The twoformulations were bioequivalent in terms of AUC but not in terms of Cmax. Cmax of the sachet wasslightly higher (23%) compared with the capsule and did not meet the criteria for bioequivalence. Tmaxwas similar with both formulations. Clinical supervision is recommended if switching between thestiripentol capsule and powder for oral suspension in sachet formulations.

Stiripentol binds extensively to circulating plasma proteins (about 99%).

Systemic exposure to stiripentol increases markedly compared to dose proportionality. Plasmaclearance decreases markedly at high doses; it falls from approximately 40 l/kg/day at the dose of600 mg/day to about 8 l/kg/day at the dose of 2,400 mg. Clearance is decreased after repeatedadministration of stiripentol, probably due to inhibition of the cytochrome P450 isoenzymesresponsible for its metabolism. The half-life of elimination was in the range of 4.5 hours to 13 hours,increasing with dose.

Stiripentol is extensively metabolized, 13 different metabolites having been found in urine. The mainmetabolic processes are demethylenation and glucuronidation, although precise identification of theenzymes involved has not yet been achieved.

On the basis of in vitro studies, the principal liver cytochrome P450 isoenzymes involved in phase 1metabolism are considered to be CYP1A2, CYP2C19 and CYP3A4.

Excretion

Most stiripentol is excreted via the kidney.

Urinary metabolites of stiripentol accounted collectively for the majority (73%) of an oral acute dosewhereas a further 13-24% was recovered in faeces as unchanged substance.

Paediatric population pharmacokinetic study

A population pharmacokinetic study was conducted in 35 children with Dravet Syndrome treated withstiripentol and two substances not known to affect stiripentol pharmacokinetics, valproate andclobazam. The median age was 7.3 years (range: 1 to 17.6 years) and the median daily dose ofstiripentol was 45.4 mg/kg/day (range: 27.1 to 89.3 mg/kg/day) received in two or three divided doses.

The data were best fitted with a one compartment model with first order absorption and eliminationprocesses. The population estimate for the absorption rate constant Ka was 2.08 hr-1 (standarddeviation of random effect = 122%). Clearance and volume of distribution were related to body weightby an allometric model with exponents of 0.433 and 1, respectively: as body weight increased from 10to 60 kg, apparent oral clearance increased from 2.60 to 5.65 L/hr and apparent volume of distributionincreased from 32.0 to 191.8 L. As a result, elimination half-life increased from 8.5hr (for 10 kg) to23.5 hr (for 60 kg).

Toxicity studies in animals (rat, monkey, mouse) have not revealed any consistent pattern of toxicityapart from liver enlargement associated with hepatocellular hypertrophy, which occurred when highdoses of stiripentol were administered to both rodents and non-rodents. This finding is considered tobe an adaptive response to a high metabolic burden on the liver.

Stiripentol was not teratogenic when tested in the rat and rabbit; in one study in the mouse, but not inseveral other similar studies, a low incidence of cleft palate formation was observed at a maternotoxicdose (800 mg/kg/day). These studies in mice and rabbits were undertaken prior to the introduction of

Good Laboratory Practice requirements. Studies in the rat on fertility and general reproductiveperformance and on pre- and postnatal development were uneventful except for a minor reduction inthe survival of pups nursed by mothers exhibiting toxic responses to stiripentol at a dose of800 mg/kg/day (see section 4.6).

Genotoxicity studies have not detected any mutagenic or clastogenic activity.

Carcinogenicity studies gave negative results in the rat. In the mouse there was only a small increasein the incidence of hepatic adenomas and carcinomas in animals treated with 200 or 600 mg/kg/day for78 weeks but not in those given 60 mg/kg/day. In view of the lack of genotoxicity of stiripentol andthe well known, special susceptibility of the mouse liver to tumour formation in the presence ofhepatic enzyme induction, this finding is not considered to indicate a risk of tumorigenicity in patients.

Capsule core

Povidone

Sodium starch glycolate

Magnesium stearate (E470b)

Gelatin

Titanium dioxide (E171)

Erythrosine (E127)

Indigotine (E132)

Shellac (E904)

Black iron oxide (E172)

Not applicable.

3 years

This medicinal product does not require any special storage conditions.

Polyethylene bottle with tamper-evident seal and child-resistant polypropylene screw cap.

Bottle of 100 capsules in cardboard cartons.

Any unused medicinal product or waste material should be disposed of in accordance with localrequirements.

Biocodex, 22 rue des Aqueducs, 94250 Gentilly, France.

EU/1/06/367/013

Date of first authorization: 04 January 2007

Date of latest renewal: 20 September 2018

Detailed information on this medicinal product is available on the website of the European Medicines

Agency http://www.ema.europa.eu